JPH0332537B2 - - Google Patents
Info
- Publication number
- JPH0332537B2 JPH0332537B2 JP10151983A JP10151983A JPH0332537B2 JP H0332537 B2 JPH0332537 B2 JP H0332537B2 JP 10151983 A JP10151983 A JP 10151983A JP 10151983 A JP10151983 A JP 10151983A JP H0332537 B2 JPH0332537 B2 JP H0332537B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- general formula
- formula
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 alkenyl carbonyloxyethyl ester derivatives of biphenylylpropionic acid Carbonyloxyethyl ester Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052751 metal Chemical class 0.000 claims description 2
- 239000002184 metal Chemical class 0.000 claims description 2
- 125000006017 1-propenyl group Chemical group 0.000 claims 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 239000013076 target substance Substances 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- JIYXQCWLSQSIJV-UHFFFAOYSA-N ethyl 2-(3-fluoro-4-phenylphenyl)propanoate Chemical compound FC1=CC(C(C)C(=O)OCC)=CC=C1C1=CC=CC=C1 JIYXQCWLSQSIJV-UHFFFAOYSA-N 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 150000005599 propionic acid derivatives Chemical class 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- VKSJVMZEQNIBNA-UHFFFAOYSA-N 2-chloroethyl propanoate Chemical compound CCC(=O)OCCCl VKSJVMZEQNIBNA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- UEKKNMHEJIWKDR-UHFFFAOYSA-N (4-phenylphenyl) propanoate Chemical compound C1=CC(OC(=O)CC)=CC=C1C1=CC=CC=C1 UEKKNMHEJIWKDR-UHFFFAOYSA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SEPRYHMNTXEWAO-XVNBXDOJSA-N 2-[2-(3-fluoro-4-phenylphenyl)propanoyloxy]ethyl (e)-but-2-enoate Chemical compound FC1=CC(C(C)C(=O)OCCOC(=O)/C=C/C)=CC=C1C1=CC=CC=C1 SEPRYHMNTXEWAO-XVNBXDOJSA-N 0.000 description 1
- IFOGYQSGWOUMCL-UHFFFAOYSA-N 2-[2-(3-fluoro-4-phenylphenyl)propanoyloxy]ethyl 3-methylbut-2-enoate Chemical compound FC1=CC(C(C(=O)OCCOC(=O)C=C(C)C)C)=CC=C1C1=CC=CC=C1 IFOGYQSGWOUMCL-UHFFFAOYSA-N 0.000 description 1
- RQIRRKMMCPIETA-UHFFFAOYSA-N 2-[2-(3-fluoro-4-phenylphenyl)propanoyloxy]ethyl hexa-2,4-dienoate Chemical compound FC1=CC(C(C)C(=O)OCCOC(=O)C=CC=CC)=CC=C1C1=CC=CC=C1 RQIRRKMMCPIETA-UHFFFAOYSA-N 0.000 description 1
- AWRZRDDAUJCCGF-NSCUHMNNSA-N 2-bromoethyl (e)-but-2-enoate Chemical compound C\C=C\C(=O)OCCBr AWRZRDDAUJCCGF-NSCUHMNNSA-N 0.000 description 1
- VKDDOZAJYWMLMZ-UHFFFAOYSA-N 2-bromoethyl 3-methylbut-2-enoate Chemical compound CC(C)=CC(=O)OCCBr VKDDOZAJYWMLMZ-UHFFFAOYSA-N 0.000 description 1
- VIRWKAJWTKAIMA-UHFFFAOYSA-N 2-chloroethyl acetate Chemical compound CC(=O)OCCCl VIRWKAJWTKAIMA-UHFFFAOYSA-N 0.000 description 1
- WHCRUHSNEOWDSM-UHFFFAOYSA-N 2-propanoyloxyethyl 2-(3-fluoro-4-phenylphenyl)propanoate Chemical compound FC1=CC(C(C)C(=O)OCCOC(=O)CC)=CC=C1C1=CC=CC=C1 WHCRUHSNEOWDSM-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- LNZMEOLVTKHUAS-UHFFFAOYSA-N cyclohexane;dichloromethane Chemical compound ClCCl.C1CCCCC1 LNZMEOLVTKHUAS-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- ZHYZQXUYZJNEHD-VQHVLOKHSA-N geranic acid Chemical compound CC(C)=CCC\C(C)=C\C(O)=O ZHYZQXUYZJNEHD-VQHVLOKHSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は一般式(I):
(式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされる新規な2−(2−
フルオロ−4−ビフエニリル)プロピオン酸のア
ルキルカルボニルオキシエチルエステル誘導体お
よびアルケニルカルボニルオキシエチルエステル
誘導体およびそれらの製造法に関する。
2−(2−フルオロ−4−ビフエニリル)プロ
ピオン酸(一般名:フルルビプロフエン、以下
FPという)は強力な消炎・鎮痛・解熱剤として
知られ、既に市販されている。
しかしながら、FPは刺激性を有するので、注
射剤およびシロツプ剤あるいは点眼剤、坐剤、ク
リーム、ブラスターなどの外用剤などの利用形態
をとり、医薬品として開発するばあいその刺激性
を減少させるのに製剤上の工夫が必要であり、そ
の製造が困難であつた。
本発明者らは、叙上の問題を解決するため鋭意
研究を重ねた結果、無刺激であり、しかも薬効が
FPの数倍ありかつ副作用の少ない安全な医薬品
を見出し、本発明を完成するにいたつた。
すなわち、FPをエステル化してえられる本発
明の化合物は刺激性を有さない。しかも本発明の
化合物は親油性が大きいため粘膜および経皮吸収
に優れ、その結果薬効の速やかな発現と増大がみ
られる。一方、製剤の一適用として油性基剤を使
用すれば薬効の増大と持続性も期待でき、医薬品
としての応用範囲が広がる。また本発明の化合物
の物理化学的性質、すなわち遊離の極性基を有さ
ないことおよび油状であることにより投与後生体
内の蛋白質とは結合し難いため、本発明の化合物
はFPと比較して投与後の生体内分布および代謝
様式が異なり、その結果炎症局所での薬物濃度が
高まり薬効が増強する。
叙上のことから、本発明の化合物は親化合物で
あるFPと比較して無刺激であり、優れた薬効を
有し、速効性および持続性の両方を兼え備えた安
全域の広い優れた医薬品である。
したがつて本発明の目的は、消炎・鎮痛・解熱
作用に優れ、副作用が少なく高い安全性を示し、
しかも広範な応用が可能な医薬品として極めて有
用な新規なFP誘導体およびその製造法を提供す
ることにある。
本発明の一般式(I)で表わされる化合物の具
体例としては、
化合物1:2−(アセチルオキシ)エチル−2−
(2−フルオロ−4−ビフエニリル)
プロピオネート、
化合物2:2−(プロピオニルオキシ)エチル−
2−(2−フルオロ−4−ビフエニリ
ル)プロピオネート、
化合物3:2−(クロトノイルオキシ)エチル−
2−(2−フルオロ−4−ビフエニリ
ル)プロピオネート、
化合物4:2−(3,3−ジメチルアクリロイル
オキシ)エチル−2−(2−フルオロ
−4−ビフエニリル)プロピオネー
ト、
化合物5:2−(2,4−ヘキサジエノイルオキ
シ)エチル−2−(2−フルオロ−4
−ビフエニリル)プロピオネート、
化合物6:2−(3,7−ジメチル−2,6−オ
クタジエノイルオキシ)エチル−2−
(2−フルオロ−4−ビフエニリル)
プロピオネート、
などがあげられる。
本発明の化合物は一般式():
(式中、Yは水素原子または金属塩である)で表
わされるプロピオン酸誘導体またはその塩と一般
式():
(式中、Rは前記と同じ、Xはフツ素、塩素、臭
素、ヨウ素などのハロゲン原子または水酸基であ
る)で表わされる化合物とを反応させるか、式
()
で表わされるビフエニリルプロピオン酸エチルヒ
ドロキシエステルと一般式(V):
(式中、Rは前記と同じである)で表わされる酸
無水物と反応させるか、あるいは一般式():
(式中、Zはフツ素、塩素、臭素、ヨウ素などの
ハロゲン原子である)で表わされるビフエニリル
プロピオン酸エチルハライドエステルと一般式
():
RCOOH ()
(式中、Rは前記と同じである)で表わされる酸
とを反応させることによりえられる。かかるエス
テル化反応は従来公知のいずれの方法をも採用す
ることができ、とくに限定はされないが、たとえ
ばつぎに示す反応を用いることが収率や工業化指
向の面から好ましい。
すなわち、一般式()で表わされるプロピオ
ン酸誘導体と一般式()で表わされるアシロキ
シエチルハライドまたは一般式()で表わされ
るエチルハライド誘導体と一般式()で表わさ
れる酸とのエステル化反応は、通常アルカリ金属
炭酸塩(炭酸カリウム、炭酸ナトリウム、重炭酸
ナトリウム、重炭酸カリウムなど)、水酸化アル
カリ(水酸基ナトリウム、水酸基カリウムなど)、
アルカリ金属水素化物(水素化ナトリウム、水素
化カリウム、水素化リチウムなど)および有機塩
基(ピリジン、トリエチルアミン、N,N−ジメ
チルアニリン、テトラメチルエチレンジアミン)
またはヨウ化ナトリウム、ヨウ化カリウムなどの
アルカリ金属ヨウ化物の存在下または不存在下
に、または15−クラウン−5、18−クラウン−6
などのクラウンエーテルまたは〔2,2,2〕−
クリプテート、〔2,2,2〕−ベンゾクリプテー
トなどの相間移動触媒の存在下非プロトン性有機
溶媒(N,N−ジメチルホルムアミド、ジメチル
スルホキシド、ヘキサメチルスルホニルトリアミ
ドなど)中またはアセトニトリル、ジクロロメタ
ン、ジクロロエタン、クロロホルム、ベンゼン、
エーテル、テトラヒドロフランなどの有機溶媒中
で行なわれる。
なお、一般式()で表わされる化合物の塩と
しては銀、銅塩またはリチウム、ナトリウム、カ
リウムなどのアルカリ金属塩が用いられる。また
前記の非プロトン性有機溶媒とエーテル、テトラ
ヒドロフラン、ベンゼン、クロロホルム、ジクロ
ロメタン、ジクロロエタンまたはアセトンなどの
混合溶媒も用いることができる。
一方、一般式()で表わされるアシロキシエ
タノールと一般式()で表わされるプロピオン
酸誘導体との反応は、中性条件下、有機溶媒中で
無触媒あるいは触媒の存在下、脱水剤の存在下ま
たは不存在下に脱水縮合させて行なわれる。使用
される有機溶媒としては、ジクロロメタン、クロ
ロホルム、エーテル、ベンゼン、テトラヒドロフ
ランなどが好ましい。使用される脱水剤として
は、N,N′−ジシクロヘキシルカルボジイミド、
1−エチル−3(3−ジメチルアミノプロピル)
カルボジイミド(水溶性カルボジイミド)または
その塩酸塩などがある。使用される触媒としては
ピリジン、ハロゲノピリジン、トリブチルアミ
ン、アミノピリジンなどがあるが、好ましくはP
−ジメチルアミノピリジンを使用することによつ
て反応収率が著しく高くなる。
また、活性エステル化法の一応用として、一般
式()で表わされるプロピオン酸誘導体をカル
ボニルジイミダゾールと反応させ、イミダゾエー
トとしたのち、一般式()で表わされるアルコ
ール誘導体と反応させて目的とするエステル化合
物をえてもよい。また、トリフエニルホスフイン
または亜リン酸トリエチルとアゾジカルボン酸ジ
アルキルエステルを用いる脱水縮合反応によつて
も高収率で目的化合物をうることができる。
一方、式()で表わされるビフエニリルプロ
ピオン酸エチルヒドロキシエステルと一般式
(V)で表わされる酸無水物との反応は、ピリジ
ン、コリジンなどの有機塩基溶媒中またはベンゼ
ン、ジメトキシエタン、トルエンなどの有機溶媒
との混合溶媒中で行なわれる。
叙上の各反応において、一般式()、一般式
(V)、一般式()で表わされる化合物の使用量
はそれぞれ一般式()、一般式()、一般式
で表わされる化合物に対して等モル以上、好まし
くは1.0〜1.5倍モルが経済的に有利である。反応
温度はとくに制限されないが、通常0〜120℃で
行なうのが好ましい。反応時間は用いる溶媒、触
媒および反応温度により変化するが、一般には、
数分から十数時間である。
叙上のごとくして製造される本発明のビフエニ
リルプロピオン酸のアルキルカルボニルオキシエ
チルエステル誘導体、アルケニルカルボニルオキ
シエチルエステル誘導体は体内での加水分解率も
優れ、強い消炎・鎮痛・解熱効果を示す。
つぎに本発明の化合物の薬理作用、UD50値、
LD50値および加水分解率を第1表に示す。
The present invention relates to general formula (I): (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms)
The present invention relates to alkylcarbonyloxyethyl ester derivatives and alkenylcarbonyloxyethyl ester derivatives of fluoro-4-biphenylyl)propionic acid and methods for producing them. 2-(2-fluoro-4-biphenylyl)propionic acid (generic name: flurbiprofen, hereafter
FP) is known as a powerful anti-inflammatory, analgesic, and antipyretic agent, and is already commercially available. However, since FP is irritating, it can be used in the form of injections, syrups, eye drops, suppositories, creams, blasters, and other external preparations to reduce its irritating properties when developed as a drug. It required some ingenuity in formulation and was difficult to manufacture. The inventors of the present invention have conducted extensive research to solve the above-mentioned problems, and have found that it is non-irritating and has medicinal efficacy.
We have discovered a safe drug that is several times more potent than FP and has fewer side effects, and have completed the present invention. That is, the compound of the present invention obtained by esterifying FP does not have irritating properties. In addition, the compounds of the present invention have high lipophilicity and are therefore excellent in mucosal and transdermal absorption, resulting in rapid onset and increase in medicinal efficacy. On the other hand, if an oily base is used as a formulation, it can be expected to increase and sustain the medicinal efficacy, expanding the range of pharmaceutical applications. Furthermore, due to the physicochemical properties of the compound of the present invention, namely, that it does not have a free polar group and is oily, it is difficult to bind to proteins in the body after administration. Subsequent biodistribution and metabolic patterns are different, resulting in increased drug concentration in the inflamed area and enhanced drug efficacy. Based on the above, the compound of the present invention is non-irritating compared to the parent compound FP, has excellent medicinal efficacy, and has both fast-acting and long-lasting properties, and is an excellent compound with a wide safety margin. It is a pharmaceutical product. Therefore, the object of the present invention is to have excellent anti-inflammatory, analgesic, and antipyretic effects, exhibit high safety with few side effects, and
Moreover, it is an object of the present invention to provide a novel FP derivative that is extremely useful as a drug that can be widely applied, and a method for producing the same. Specific examples of the compound represented by the general formula (I) of the present invention include Compound 1: 2-(acetyloxy)ethyl-2-
(2-fluoro-4-biphenylyl)
Propionate, compound 2: 2-(propionyloxy)ethyl-
2-(2-fluoro-4-biphenylyl)propionate, compound 3: 2-(crotonoyloxy)ethyl-
2-(2-fluoro-4-biphenylyl)propionate, Compound 4: 2-(3,3-dimethylacryloyloxy)ethyl-2-(2-fluoro-4-biphenylyl)propionate, Compound 5: 2-(2, 4-hexadienoyloxy)ethyl-2-(2-fluoro-4
-biphenylyl)propionate, compound 6: 2-(3,7-dimethyl-2,6-octadienoyloxy)ethyl-2-
(2-fluoro-4-biphenylyl)
Examples include propionate. The compound of the present invention has the general formula (): (In the formula, Y is a hydrogen atom or a metal salt.) A propionic acid derivative or its salt and the general formula (): (In the formula, R is the same as above, and X is a halogen atom such as fluorine, chlorine, bromine, or iodine, or a hydroxyl group.) or Biphenylylpropionate ethyl hydroxyester represented by general formula (V): (wherein R is the same as above) or the general formula (): (In the formula, Z is a halogen atom such as fluorine, chlorine, bromine, iodine, etc.) Biphenylylpropionate ethyl halide ester and the general formula (): RCOOH () (wherein, R is the same as above) It can be obtained by reacting with an acid represented by Any conventionally known method can be used for this esterification reaction, and although it is not particularly limited, it is preferable to use the following reaction, for example, from the viewpoint of yield and industrialization. That is, the esterification reaction between the propionic acid derivative represented by the general formula () and the acyloxyethyl halide represented by the general formula () or the ethyl halide derivative represented by the general formula () and the acid represented by the general formula () is , usually alkali metal carbonates (potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, etc.), alkali hydroxides (sodium hydroxide, potassium hydroxide, etc.),
Alkali metal hydrides (sodium hydride, potassium hydride, lithium hydride, etc.) and organic bases (pyridine, triethylamine, N,N-dimethylaniline, tetramethylethylenediamine)
or in the presence or absence of an alkali metal iodide such as sodium iodide, potassium iodide, or 15-crown-5, 18-crown-6
Crown ethers such as or [2,2,2]-
cryptate, [2,2,2]-benzocryptate, etc. in an aprotic organic solvent (N,N-dimethylformamide, dimethylsulfoxide, hexamethylsulfonyltriamide, etc.) in the presence of a phase transfer catalyst such as acetonitrile, dichloromethane, dichloroethane, chloroform, benzene,
It is carried out in an organic solvent such as ether or tetrahydrofuran. Incidentally, as the salt of the compound represented by the general formula (), a silver, copper salt, or an alkali metal salt such as lithium, sodium, or potassium is used. Further, a mixed solvent such as the above-mentioned aprotic organic solvent and ether, tetrahydrofuran, benzene, chloroform, dichloromethane, dichloroethane or acetone can also be used. On the other hand, the reaction between acyloxyethanol represented by the general formula () and the propionic acid derivative represented by the general formula () can be carried out under neutral conditions in an organic solvent without or in the presence of a catalyst, or in the presence of a dehydrating agent. Alternatively, dehydration condensation may be carried out in the absence of the compound. Preferred organic solvents used include dichloromethane, chloroform, ether, benzene, and tetrahydrofuran. The dehydrating agent used is N,N'-dicyclohexylcarbodiimide,
1-ethyl-3(3-dimethylaminopropyl)
Examples include carbodiimide (water-soluble carbodiimide) or its hydrochloride. Catalysts used include pyridine, halogenopyridine, tributylamine, aminopyridine, etc., but preferably P
- By using dimethylaminopyridine, the reaction yield is significantly increased. In addition, as an application of the active esterification method, a propionic acid derivative represented by the general formula () is reacted with carbonyldiimidazole to form an imidazoate, and then reacted with an alcohol derivative represented by the general formula () to obtain the desired product. Ester compounds may also be obtained. The target compound can also be obtained in high yield by a dehydration condensation reaction using triphenylphosphine or triethyl phosphite and azodicarboxylic acid dialkyl ester. On the other hand, the reaction between biphenylylpropionate ethyl hydroxyester represented by formula () and the acid anhydride represented by general formula (V) can be carried out in an organic base solvent such as pyridine or collidine or in benzene, dimethoxyethane, toluene, etc. It is carried out in a mixed solvent with an organic solvent. In each reaction described above, the amounts of compounds represented by general formula (), general formula (V), and general formula () to be used are relative to the compounds represented by general formula (), general formula (), and general formula, respectively. Equimolar or more, preferably 1.0 to 1.5 times the molar amount is economically advantageous. The reaction temperature is not particularly limited, but it is usually preferably carried out at 0 to 120°C. The reaction time varies depending on the solvent, catalyst, and reaction temperature used, but in general,
The duration ranges from a few minutes to more than ten hours. The alkylcarbonyloxyethyl ester derivatives and alkenylcarbonyloxyethyl ester derivatives of biphenylylpropionic acid of the present invention produced as described above have an excellent rate of hydrolysis in the body and exhibit strong anti-inflammatory, analgesic, and antipyretic effects. . Next, the pharmacological action of the compound of the present invention, the UD 50 value,
The LD 50 values and hydrolysis rates are shown in Table 1.
2−(2−フルオロ−4−ビフエニリル)プロ
ピオン酸(以下、FPという)12.2g(50ミリモル)
を乾燥ジメチルホルムアミド45mlに溶解し、無水
炭酸カリウム6.9(50ミリモル)を加え、氷冷下エ
チレンブロモヒドリン6.25(50ミリモル)を滴下
し、滴下終了後60〜70℃で15時間加熱撹拌した。
反応混合物を氷冷し、無機物を別したのち溶
媒を減圧留去した。残渣にジエチルエーテル50ml
を加え、水、10%炭酸ナトリウム水溶液、飽和食
塩水で順次洗浄し、有機層を無水硫酸マグネシウ
ムで乾燥後溶媒を減圧留去し、13.8gの透明油状
物をえた。
えられた油状物をシリカゲルカラムクロマト
(メルク社製キーゼルゲル60F;展開溶媒:ジ
クロロメタンジクロロメタン:エーテル(9:
1)ジクロロメタン:エーテル(8:2))に
て精製し、融点73〜75℃の白色結晶である目的物
質9.97g(収率:69.2%)をえた。
質量スペクトル(直接導入、20eV)
m/e288(M+)、244、199(base peak)、184、
178、45
参考例 2
〔2−ブロモエチル−2−(2−フルオロ−4
−ビフエニリル)プロピオネートの製造〕
FP12.2g(50ミリモル)をジクロロメタン40ml
に溶解し、0℃撹拌下、これにエチレンブロモヒ
ドリン6.25g(50ミリモル)とp−ジメチルアミノ
ピリジン0.3g(2.5ミリモル)を加え、ついでジク
ロロメタンに溶解したジシクロヘキシルカルボジ
イミド10.3g(50ミリモル)を滴下し、滴下終了後
室温にて30分間加熱撹拌した。
反応混合物を氷冷して不溶物を別したのち、
有機層を0.1N塩酸、飽和炭酸水素ナトリウム水
溶液、飽和食塩水で順次洗浄し、有機層を無水硫
酸マグネシウムで乾燥後溶媒を減圧留去し、析出
したジシクロヘキシルウレアを別後えられた黄
色油状物を参考例1と同様に精製して透明油状の
目的物質15.6g(収率:89%)をえた。
質量スペクトル(直接導入、20eV)
m/e351(M+)、353(M+2)、244、199(base
peak)184、178、108、110
実施例 1
〔2−(アセチルオキシ)エチル−2−(2−フ
ルオロ−4−ビフエニリル)プロピオネート
(化合物1)の製造〕
FP2.44g(10ミリモル)を乾燥ジクロロメタン
25mlに溶解し0℃撹拌下これに2−〔アセチルオ
キシ)エチルアルコール(1.04g:10ミリモル)
とp−ジメチルアミノピリジン0.13g(1ミリモ
ル)を加え、乾燥ジクロロメタンに溶解したジシ
クロヘキシルカルボジイミド2.3g(11ミリモル)
を滴下し、滴下終了後室温で1時間撹拌した。
反応混合物を氷冷して不溶物を別したのち、
有機層を0.1N塩酸、飽和炭酸水素ナトリウム水
溶液、飽和食塩水にて順次洗浄し、有機層を無水
硫酸マグネシウムで乾燥後溶媒を減圧留去し、析
出したジシクロヘキシルウレアを別後、えられ
た透明油状物を減圧蒸留によつて精製し、沸点
234〜238℃/1mmHgの留分を集め透明油状物の
目的物質2.6g(収率:80%)をえた。
えられた目的物質の特性値を示す。
元素分析値:C19H19FO4(分子量:330.4として)
計算値(%):C69.07 H5.75
実測値(%):C69.28 H5.77
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.55(d、3H、
2-(2-fluoro-4-biphenylyl)propionic acid (hereinafter referred to as FP) 12.2g (50 mmol)
was dissolved in 45 ml of dry dimethylformamide, 6.9 (50 mmol) of anhydrous potassium carbonate was added, and 6.25 (50 mmol) of ethylene bromohydrin was added dropwise under ice-cooling. After the dropwise addition was completed, the mixture was heated and stirred at 60 to 70°C for 15 hours. The reaction mixture was ice-cooled, the inorganic substances were separated, and the solvent was distilled off under reduced pressure. Add 50ml of diethyl ether to the residue.
The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 13.8 g of a transparent oil. The obtained oil was purified by silica gel column chromatography (Merck Kieselgel 60F; developing solvent: dichloromethane dichloromethane:ether (9:
1) Purification with dichloromethane:ether (8:2)) to obtain 9.97 g (yield: 69.2%) of the target substance as white crystals with a melting point of 73-75°C. Mass spectrum (direct introduction, 20eV) m/e288 (M + ), 244, 199 (base peak), 184,
178, 45 Reference example 2 [2-bromoethyl-2-(2-fluoro-4
-Production of biphenylyl) propionate] 12.2 g (50 mmol) of FP was added to 40 ml of dichloromethane.
6.25 g (50 mmol) of ethylene bromohydrin and 0.3 g (2.5 mmol) of p-dimethylaminopyridine were added thereto under stirring at 0°C, followed by 10.3 g (50 mmol) of dicyclohexylcarbodiimide dissolved in dichloromethane. After the dropwise addition was completed, the mixture was heated and stirred at room temperature for 30 minutes. After cooling the reaction mixture on ice and separating insoluble materials,
The organic layer was washed successively with 0.1N hydrochloric acid, a saturated aqueous sodium bicarbonate solution, and saturated brine, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to separate the precipitated dicyclohexylurea, and a yellow oil was obtained. was purified in the same manner as in Reference Example 1 to obtain 15.6 g (yield: 89%) of the target substance as a transparent oil. Mass spectrum (direct introduction, 20eV) m/e351 (M + ), 353 (M+2), 244, 199 (base
peak) 184, 178, 108, 110 Example 1 [Production of 2-(acetyloxy)ethyl-2-(2-fluoro-4-biphenylyl)propionate (compound 1)] 2.44 g (10 mmol) of FP was added to dry dichloromethane.
2-[acetyloxy)ethyl alcohol (1.04 g: 10 mmol) was dissolved in 25 ml and stirred at 0°C.
and 0.13 g (1 mmol) of p-dimethylaminopyridine and 2.3 g (11 mmol) of dicyclohexylcarbodiimide dissolved in dry dichloromethane.
was added dropwise, and after the addition was completed, the mixture was stirred at room temperature for 1 hour. After cooling the reaction mixture on ice and separating insoluble materials,
The organic layer was washed successively with 0.1N hydrochloric acid, a saturated aqueous sodium bicarbonate solution, and saturated brine, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the precipitated dicyclohexylurea was separated, resulting in a transparent solution. The oil is purified by vacuum distillation and the boiling point
Fractions at 234-238°C/1 mmHg were collected to obtain 2.6 g (yield: 80%) of the desired substance as a transparent oil. The characteristic values of the obtained target substance are shown. Elemental analysis value: C 19 H 19 FO 4 (molecular weight: 330.4) Calculated value (%): C69.07 H5.75 Actual value (%): C69.28 H5.77 Nuclear magnetic resonance spectrum (in CCl 4 , internal Standard: Tetramethylsilane) (ppm) δ1.55 (d, 3H,
【式】) δ1.96(s、3H、【formula】) δ1.96(s, 3H,
【式】) δ3.74(q、1H、【formula】) δ3.74(q, 1H,
【式】) δ4.20(s、4H、【formula】) δ4.20(s, 4H,
【式】)
δ6.90〜7.42(m、8H、アロマテイツクプロト
ン)
質量スペクトル(直接導入、20eV)
m/e330(M+)
m/e226
m/e199〔base peak、[Formula]) δ6.90~7.42 (m, 8H, aromatic proton) Mass spectrum (direct introduction, 20eV) m/e330 (M + ) m/e226 m/e199 [base peak,
【式】〕 m/e43〔−COCH3〕+ m/e87[Formula]] m/e43 [−COCH 3 ] + m/e87
FP2.44g(10ミリモル)を無水ジメチルホルム
アミド(以下、DMFという)25mlに溶解し、無
水炭酸カリウム1.38g(10ミリモル)を加え、室温
下1時間撹拌した。ついで蒸留精製した2−(プ
ロピオニルオキシ)エチルクロライド1.77g(13ミ
リモル)を滴下し、滴下終了後40℃〜50℃で1時
間撹拌した。
反応混合物を氷冷し、無機物を別したのち溶
媒を減圧留去した。残渣にジエチルエーテル50ml
を加え水、10%炭酸ナトリウム水溶液、飽和食塩
水で順次洗浄し、有機層を無水硫酸マグネシウム
で乾燥後、溶媒を減圧留去した。えられた透明油
状物を減圧留去にて精製し、沸点225〜228℃/
0.5mmHgの留分を集め透明油状の目的物質2.5g
(収率74%)をえた。
えられた目的物質の特性値を示す。
元素分析値:C20H21FO4(分子量:344.4とし
て)
計算値(%):C69.69 H6.10
実測値(%):C69.90 H6.12
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.08(t、3H、−CH2CH〜3)
δ1.52(d、3H、
2.44 g (10 mmol) of FP was dissolved in 25 ml of anhydrous dimethylformamide (hereinafter referred to as DMF), 1.38 g (10 mmol) of anhydrous potassium carbonate was added, and the mixture was stirred at room temperature for 1 hour. Then, 1.77 g (13 mmol) of 2-(propionyloxy)ethyl chloride purified by distillation was added dropwise, and after the dropwise addition was completed, the mixture was stirred at 40°C to 50°C for 1 hour. The reaction mixture was ice-cooled, the inorganic substances were separated, and the solvent was distilled off under reduced pressure. Add 50ml of diethyl ether to the residue.
The organic layer was washed with water, a 10% aqueous sodium carbonate solution, and saturated brine, and the organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resulting transparent oil was purified by distillation under reduced pressure to a boiling point of 225-228℃/
Collect the 0.5mmHg fraction and collect 2.5g of the target substance as a transparent oil.
(yield 74%). The characteristic values of the obtained target substance are shown. Elemental analysis value: C 20 H 21 FO 4 (molecular weight: 344.4) Calculated value (%): C69.69 H6.10 Actual value (%): C69.90 H6.12 Nuclear magnetic resonance spectrum (in CCl 4 , internal Standard: Tetramethylsilane) (ppm) δ1.08 (t, 3H, -CH2CH ~ 3 ) δ1.52 (d, 3H,
【式】) δ2.26(q、2H、−CH〜2CH3) δ3.75(q、1H、[Formula]) δ2.26 (q, 2H, -CH~ 2 CH 3 ) δ3.75 (q, 1H,
【式】) δ4.22(s、4H、【formula】) δ4.22(s, 4H,
【式】)
δ6.90〜7.42(m、8H、アロマテイツクプロト
ン)
質量スペクトル(直接導入、20eV)
m/e344(M+)
m/e226
m/e199〔base peak
[Formula]) δ6.90-7.42 (m, 8H, aromatic proton) Mass spectrum (direct introduction, 20eV) m/e344 (M + ) m/e226 m/e199 [base peak
【式】〕 m/e101【formula】〕 m/e101
FP3.66g(15ミリモル)、乾燥DMF10ml、無水
炭酸カリウム2.07g(15ミリモル)および2−(ク
ロトノイルオキシ)−エチルブロミド2.89g(15ミ
リモル)を用いたほかは実施例2と同様にして反
応後処理、精製して沸点205〜215℃/1.5mmHgの
透明油状である目的物質3.39g(収率:63.4%)を
えた。
えられた目的物質の特性値を示す。
元素分析値:C21H21FO4(分子量356.4として)
計算値(%):C70.77 H5.89
実測値(%):C70.98 H5.91
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.40(d、3H、
The reaction was carried out in the same manner as in Example 2, except that 3.66 g (15 mmol) of FP, 10 ml of dry DMF, 2.07 g (15 mmol) of anhydrous potassium carbonate, and 2.89 g (15 mmol) of 2-(crotonoyloxy)-ethyl bromide were used. After post-treatment and purification, 3.39 g (yield: 63.4%) of the desired substance was obtained as a transparent oil with a boiling point of 205-215°C/1.5 mmHg. The characteristic values of the obtained target substance are shown. Elemental analysis value: C 21 H 21 FO 4 (as molecular weight 356.4) Calculated value (%): C70.77 H5.89 Actual value (%): C70.98 H5.91 Nuclear magnetic resonance spectrum (in CCl 4 , internal standard : Tetramethylsilane) (ppm) δ1.40 (d, 3H,
【式】) δ1.72(dd、3H、オレフイニツクCH〜3) δ3.57(q、1H、[Formula]) δ1.72 (dd, 3H, Olefinik CH ~ 3 ) δ3.57 (q, 1H,
【式】) δ4.06(s、4H、【formula】) δ4.06(s, 4H,
【式】)
δ5.54、5.51(dd、1H、オレフイニツクプロト
ン)
δ6.44〜7.33(m、9H、アロマテイツク、オレフ
イニツクプロトン)
質量スペクトル(直接導入、20eV)
m/e356(M+)
m/e226
m/e199〔base peak
[Formula]) δ5.54, 5.51 (dd, 1H, olefinik proton) δ6.44-7.33 (m, 9H, aromatic, olefinik proton) Mass spectrum (direct introduction, 20eV) m/e356 (M + ) m/e226 m/e199 [base peak
【式】〕 m/e113【formula】〕 m/e113
FP3.66g(15ミリモル)、乾燥DMF20ml、無水
炭酸カリウム2.07g(15ミリモル)および2−
(3,3−ジメチルアクロリロイルオキシ)エチ
ルブロマイド3.0g(15ミリモル)を用いたほかは
実施例2と同様にして反応、後処理、精製して沸
点225〜228℃/0.8mmHgの透明油状物である目的
物質3.31g(収率59.6%)をえた。
えられた目的物質の特性値を示す。
元素分析値:C22H23FO4(分子量370.5として)
計算値(%):C71.32 H6.21
実測値(%):C71.53 H6.24
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.44(d、3H、
3.66 g (15 mmol) of FP, 20 ml of dry DMF, 2.07 g (15 mmol) of anhydrous potassium carbonate and 2-
The reaction, post-treatment and purification were carried out in the same manner as in Example 2 except that 3.0 g (15 mmol) of (3,3-dimethylacryloyloxy)ethyl bromide was used, resulting in a transparent oil with a boiling point of 225-228°C/0.8 mmHg. 3.31g (yield 59.6%) of the target substance was obtained. The characteristic values of the obtained target substance are shown. Elemental analysis value: C 22 H 23 FO 4 (as molecular weight 370.5) Calculated value (%): C71.32 H6.21 Actual value (%): C71.53 H6.24 Nuclear magnetic resonance spectrum (in CCl 4 , internal standard : Tetramethylsilane) (ppm) δ1.44 (d, 3H,
【式】) δ1.72(s、3H、オレフイニツク−CH3) δ2.03(s、3H、オレフイニツク−CH3) δ3.62(q、1H、[Formula]) δ1.72 (s, 3H, olefinik - CH 3 ) δ2.03 (s, 3H, olefinik - CH 3 ) δ3.62 (q, 1H,
【式】) δ4.08(s、4H、【formula】) δ4.08(s, 4H,
【式】)
δ5.40(m、1H、オレフイニツクプロトン)
δ6.82〜7.52(m、8H、アロマテイツクプロト
ン)
質量スペクトル(直接導入、20eV)
m/e370(M+)
m/e226
m/e199〔base peak
〕
m/e127[Formula]) δ5.40 (m, 1H, olefinic proton) δ6.82-7.52 (m, 8H, aromatic proton) Mass spectrum (direct introduction, 20eV) m/e370 (M + ) m/e226 m/e199〔base peak ] m/e127
3,7−ジメチル−2,6−オクタジエノイツ
クアシド1.68g(10ミリモル)、乾燥DMF10ml、無
水炭酸カリウム1.38g(10ミリモル)および2−ブ
ロモエチル−2−(2−フルオロ−4−ビフエニ
リル)プロピオネート3.51g(10ミリモル)を用い
たほかは実施例2と同様にして反応、後処理し、
えられた残渣をシリカゲルカラムクロマト(メル
ク社製キーゼルゲル60F;60g、展開溶媒:ジク
ロロメタン−シクロヘキサン混合溶媒)にて精製
し透明油状の目的物質3.1g(収率:83.7%)をえ
た。沸点250℃/1mmHg以上
えられた目的物質の特性値を示す。
元素分析値:C27H31FO4(分子量438.6として)
計算値(%):C73.94 H7.07
実測値(%):C74.16 H7.06
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.44(d、3H、
1.68 g (10 mmol) of 3,7-dimethyl-2,6-octadienoic acid, 10 ml of dry DMF, 1.38 g (10 mmol) of anhydrous potassium carbonate and 2-bromoethyl-2-(2-fluoro-4-biphenylyl) The reaction and post-treatment were carried out in the same manner as in Example 2 except that 3.51 g (10 mmol) of propionate was used.
The resulting residue was purified by silica gel column chromatography (Merck Kieselgel 60F; 60 g, developing solvent: dichloromethane-cyclohexane mixed solvent) to obtain 3.1 g (yield: 83.7%) of the target substance as a transparent oil. Boiling point: 250℃/1mmHg or higher Indicates the characteristic value of the target substance obtained. Elemental analysis value: C 27 H 31 FO 4 (as molecular weight 438.6) Calculated value (%): C73.94 H7.07 Actual value (%): C74.16 H7.06 Nuclear magnetic resonance spectrum (in CCl 4 , internal standard : Tetramethylsilane) (ppm) δ1.44 (d, 3H,
【式】)
δ1.46、1.55(ss、6H、オレフイニツク−CH3×
2)
δ1.96(m、7H、オレフイニツク−CH〜3、オレ
フイニツク、−CH〜2−CH〜2−)
δ3.50(q、1H、[Formula]) δ1.46, 1.55 (ss, 6H, Olefinik − CH 3 ×
2) δ1.96 (m, 7H, olefinik-CH~ 3 , olefinik, -CH ~ 2 -CH~ 2 -) δ3.50 (q, 1H,
【式】) δ3.96(s、4H、【formula】) δ3.96(s, 4H,
【式】)
δ4.66〜4.92(m、1H、オレフイニツクプロト
ン)
δ5.24(s、1H、オレフイニツクプロトン)
δ6.64〜7.18(m、8H、アロマテイツクプロト
ン)
質量スペクトル(直接導入、20eV)
m/e438(M+)
m/e226
m/e199〔base peak
[Formula]) δ4.66~4.92 (m, 1H, olefinik proton) δ5.24 (s, 1H, olefinik proton) δ6.64~7.18 (m, 8H, aromatic proton) Mass spectrum ( Direct introduction, 20eV) m/e438 (M + ) m/e226 m/e199 [base peak
乾燥アセトニトリル200mlに18−クラウン−
60.1g、ソルビン酸カリウム1.5g(20ミリモル)お
よび2−ブロモエチル−2−2−(2−フルオロ
−4−ビフエニリル)プロピオネート3.5g(10ミ
リモル)を加え、50℃にて8時間加熱撹拌した。
以下、常法に従い、実施例5と同様にして後処
理、精製して融点59〜61℃の白色結晶である目的
物質3.5g(収率:91.6%)をえた。
えられた目的物質の特性値を示す。
元素分析値:C23H33FO4(分子量382.3として)
計算値(%):C72.26 H6.02
実測値(%):C72.40 H6.04
核磁気共鳴スペクトル(CCl4中、内部標準:テ
トラメチルシラン)(ppm)
δ1.44(d、3H、
18 crowns in 200 ml of dry acetonitrile
60.1 g, 1.5 g (20 mmol) of potassium sorbate, and 3.5 g (10 mmol) of 2-bromoethyl-2-2-(2-fluoro-4-biphenylyl)propionate were added, and the mixture was heated and stirred at 50° C. for 8 hours.
Thereafter, the product was post-treated and purified in the same manner as in Example 5 according to conventional methods to obtain 3.5 g (yield: 91.6%) of the desired substance as white crystals with a melting point of 59-61°C. The characteristic values of the obtained target substance are shown. Elemental analysis value: C 23 H 33 FO 4 (as molecular weight 382.3) Calculated value (%): C72.26 H6.02 Actual value (%): C72.40 H6.04 Nuclear magnetic resonance spectrum (in CCl 4 , internal standard : Tetramethylsilane) (ppm) δ1.44 (d, 3H,
【式】) δ1.71(d、3H、オレフイニツク−CH3) δ3.48(q、1H、[Formula]) δ1.71 (d, 3H, Olefinik-CH 3 ) δ3.48 (q, 1H,
【式】) δ4.00(s、4H、【formula】) δ4.00(s, 4H,
【式】)
δ5.24、5.38(d、1H、オレフイニツクプロト
ン)
δ5.63〜5.72(m、2H、オレフイニツクプロト
ン)
δ6.60〜7.18(m、9H、アロマテイツク、オレフ
イニツクプロトン)
質量スペクトル(直接導入、20eV)
m/e382(M+)
m/e271
[Formula]) δ5.24, 5.38 (d, 1H, olefinik proton) δ5.63~5.72 (m, 2H, olefinik proton) δ6.60~7.18 (m, 9H, aromatik, olefinik proton) ) Mass spectrum (direct introduction, 20eV) m/e382 (M + ) m/e271
【式】
m/e226(base peak)
m/e199
[Formula] m/e226 (base peak) m/e199
2−ヒドロキシエチル−2−(2−フルオロ−
4−ビフエニリル)プロピオネート7.55g(26.2ミ
リモル)を乾燥ピリジン35mlに溶解し、氷冷しな
がら無水酢酸4g(39.3ミリモル)を滴下し、滴下
終了後40℃で3時間加熱撹拌し、反応混合物を冷
却したのち、氷水中に注ぎ、ジエチルエーテル
400mlで抽出した。このものを10%塩酸および水
で順次洗浄し、有機層を無水硫酸マグネシウムで
乾燥後、溶媒を減圧留去し、えられた透明油状物
を減圧蒸留にて精製し、透明油状の目的物質
7.61g(収率:88%)をえた。
えられた目的物質の特性値は実施例1のものと
一致した。
実施例 8
〔2−(アセチルオキシ)エチル−2−(2−フ
ルオロ−4−ビフエニリル)プロピオネート
(化合物1)の製造〕
乾燥アセトニトリル100mlにFPのカリウム塩
2.82g(10ミリモル)、18−クラウン−60.1gおよび
アセチルオキシエチルクロライド1.22g(10ミリモ
ル)を加え、室温下8時間撹拌した。
以下、常法に従い後処理し、実施例1と同様に
して精製を行ない、透明油状の目的物質1.48g(収
率:44.8%)をえた。
えられた目的物質の特性値は実施例1のものと
一致した。
実施例 9
〔2−(プロピオニルオキシ)エチル−2−(2
−フルオロ−4−ビフエニリル)プロピオネー
ト(化合物2)の製造〕
乾燥アセトニトリル100mlにFPのカリウム塩
2.82g(10ミリモル)、プロピオニルオキシエチル
クロライド1.7g(10ミリモル)、トリエチルアミン
1g、ヨウ化カリウム1.6gを加え、60℃で5時間加
熱撹拌した。
以下、常法に従い後処理し、減圧下蒸留して透
明油状の目的物2.86g(収率:83%)をえた。
えられた目的物質の特性値は実施例2のものと
一致した。
2-hydroxyethyl-2-(2-fluoro-
Dissolve 7.55 g (26.2 mmol) of 4-biphenylyl propionate in 35 ml of dry pyridine, dropwise add 4 g (39.3 mmol) of acetic anhydride while cooling with ice, and after the dropwise addition, heat and stir at 40°C for 3 hours to cool the reaction mixture. After that, pour it into ice water and add diethyl ether.
Extracted with 400ml. This was washed sequentially with 10% hydrochloric acid and water, the organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting transparent oil was purified by vacuum distillation to obtain the target substance in the form of a transparent oil.
7.61g (yield: 88%) was obtained. The characteristic values of the target substance obtained were consistent with those of Example 1. Example 8 [Production of 2-(acetyloxy)ethyl-2-(2-fluoro-4-biphenylyl)propionate (compound 1)] Potassium salt of FP in 100 ml of dry acetonitrile
2.82 g (10 mmol), 60.1 g of 18-crown, and 1.22 g (10 mmol) of acetyloxyethyl chloride were added, and the mixture was stirred at room temperature for 8 hours. Thereafter, the product was post-treated according to a conventional method and purified in the same manner as in Example 1 to obtain 1.48 g (yield: 44.8%) of the desired substance in the form of a transparent oil. The characteristic values of the target substance obtained were consistent with those of Example 1. Example 9 [2-(propionyloxy)ethyl-2-(2
-Production of fluoro-4-biphenylyl) propionate (compound 2)] Potassium salt of FP in 100 ml of dry acetonitrile
2.82g (10mmol), propionyloxyethyl chloride 1.7g (10mmol), triethylamine
1 g of potassium iodide and 1.6 g of potassium iodide were added thereto, and the mixture was heated and stirred at 60°C for 5 hours. Thereafter, the product was worked up according to a conventional method and distilled under reduced pressure to obtain 2.86 g (yield: 83%) of the desired product as a transparent oil. The obtained characteristic values of the target substance were consistent with those of Example 2.
Claims (1)
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされるビフエニリルプロ
ピオン酸のアルキルカルボニルオキシエチルエス
テル誘導体およびアルケニルカルボニルオキシエ
チルエステル誘導体。 2 前記Rがメチル基、エチル基、1−プロペニ
ル基、2−メチル−1−プロペニル基、1,3−
ペンタジエニル基、2,6−ジメチル−1.5−ヘ
プタジエニル基よりなる群から選ばれた置換基で
ある特許請求の範囲第一項記載の誘導体。 3 一般式(): (式中、Yは水素原子または金属塩)で表わされ
る2−(2−フルオロ−4−ビフエニリル)プロ
ピオン酸またはその塩と一般式(): (式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基、または2〜7個の炭素原子を有するア
ルケニル基、Xはフツ素、塩素、臭素またはヨウ
素などのハロゲン原子または水酸基である)で表
わされる化合物とを反応させることを特徴とする
一般式(I): (式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされるビフエニリルプロ
ピオン酸のアルキルカルボニルオキシエチルエス
テル誘導体およびアルケニルカルボニルオキシエ
チルエステル誘導体の製造法。 4 式(): で表わされるビフエニリルプロピオン酸エチルヒ
ドロキシエステルと 一般式(V): (式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされる酸無水物とを反応
させることを特徴とする 一般式(I): (式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされるビフエニリルプロ
ピオン酸のアルキルカルボニルオキシエチルエス
テル誘導体およびアルケニルカルボニルオキシエ
チルエステル誘導体の製造法。 5 一般式(): (式中、Zはフツ素、塩素、臭素、ヨウ素などの
ハロゲン原子である)で表わされるビフエニリル
プロピオン酸エチルハライドエステルと一般式
(): RCOOH () (式中、Rは1〜2個の炭素原子を有する低級ア
ルキル基または2〜7個の炭素原子を有するアル
ケニル基である)で表わされる酸とを反応させる
ことを特徴とする一般式(I): (式中、Rは前記と同じ)で表わされるビフエニ
リルプロピオン酸のアルキルカルボニルオキシエ
チルエステル誘導体およびアルケニルカルボニル
オキシエチルエステル誘導体の製造法。[Claims] 1 General formula (I): (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms) and alkenyl carbonyloxyethyl ester derivatives of biphenylylpropionic acid Carbonyloxyethyl ester derivative. 2 The above R is a methyl group, an ethyl group, a 1-propenyl group, a 2-methyl-1-propenyl group, a 1,3-
The derivative according to claim 1, which is a substituent selected from the group consisting of a pentadienyl group and a 2,6-dimethyl-1.5-heptadienyl group. 3 General formula (): (wherein, Y is a hydrogen atom or a metal salt) 2-(2-fluoro-4-biphenylyl)propionic acid or its salt and the general formula (): (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms, and X is a halogen atom such as fluorine, chlorine, bromine or iodine, or a hydroxyl group. ) General formula (I) characterized by reacting with a compound represented by: (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms) and alkenyl carbonyloxyethyl ester derivatives of biphenylylpropionic acid Method for producing carbonyloxyethyl ester derivative. 4 Formula (): Biphenylylpropionate ethyl hydroxyester represented by general formula (V): (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms) (I): (wherein R is a lower alkyl group having 1 to 2 carbon atoms or an alkenyl group having 2 to 7 carbon atoms) and alkenyl carbonyloxyethyl ester derivatives of biphenylylpropionic acid Method for producing carbonyloxyethyl ester derivative. 5 General formula (): (wherein, Z is a halogen atom such as fluorine, chlorine, bromine, iodine, etc.) and the general formula (): RCOOH () (wherein, R is 1 to 2 General formula (I) characterized by reacting with an acid represented by a lower alkyl group having 5 carbon atoms or an alkenyl group having 2 to 7 carbon atoms: A method for producing an alkylcarbonyloxyethyl ester derivative and an alkenylcarbonyloxyethyl ester derivative of biphenylylpropionic acid represented by the formula (wherein R is the same as above).
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10151983A JPS59225143A (en) | 1983-06-06 | 1983-06-06 | Biphenylylpropionic acid derivative and its preparation |
AU18772/83A AU559633B2 (en) | 1982-09-10 | 1983-09-06 | Biphenylyl propionic acid derivatives |
EP19830108796 EP0103265B1 (en) | 1982-09-10 | 1983-09-07 | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same |
NZ20551683A NZ205516A (en) | 1982-09-10 | 1983-09-07 | Biphenylpropionic acid derivatives and pharmaceutical compositions |
CA000436224A CA1201127A (en) | 1982-09-10 | 1983-09-07 | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same |
DE8383108796T DE3368046D1 (en) | 1982-09-10 | 1983-09-07 | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same |
AT83108796T ATE23988T1 (en) | 1982-09-10 | 1983-09-07 | BIPHENYLPROPIONIC ACID DERIVATIVE, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITION CONTAINING IT. |
ES525498A ES8502962A1 (en) | 1982-09-10 | 1983-09-08 | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same. |
US06/531,535 US4699925A (en) | 1982-09-10 | 1983-09-12 | Biphenylylpropionic acid derivative and pharmaceutical composition containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10151983A JPS59225143A (en) | 1983-06-06 | 1983-06-06 | Biphenylylpropionic acid derivative and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59225143A JPS59225143A (en) | 1984-12-18 |
JPH0332537B2 true JPH0332537B2 (en) | 1991-05-13 |
Family
ID=14302757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10151983A Granted JPS59225143A (en) | 1982-09-10 | 1983-06-06 | Biphenylylpropionic acid derivative and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59225143A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2918366B1 (en) * | 2007-07-02 | 2009-10-23 | Synkem Soc Par Actions Simplif | NEW PROCESS FOR THE PREPARATION OF FENOFIBRATE |
-
1983
- 1983-06-06 JP JP10151983A patent/JPS59225143A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS59225143A (en) | 1984-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0257546B2 (en) | ||
US4699925A (en) | Biphenylylpropionic acid derivative and pharmaceutical composition containing the same | |
JPS6215057B2 (en) | ||
JPH0332537B2 (en) | ||
JP2622887B2 (en) | Isoxazole derivative and method for producing the same | |
US4008269A (en) | Phenylacetic acids | |
US5750778A (en) | Fungicide intermediates | |
EP0103265B1 (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
EP0051981B1 (en) | Esters of n-(4'-hydroxyphenyl)acetamide with 5-benzoyl-1-methylpyrrole-2-acetic acids | |
JPS6126556B2 (en) | ||
JPH0235740B2 (en) | ||
CA1176644A (en) | Pharmaceutical compound and process for the manufacture thereof | |
KR840001569B1 (en) | Process for the preparation of prostaglandine derivatives of 2-pge2 2-pgf2 series | |
CA1202318A (en) | Ester derivatives of acetylsalicylic acid | |
EA010020B1 (en) | Carboxylic acid compound and medicine containing the same | |
JPH0676361B2 (en) | Pharmaceutical composition for treating or preventing atherosclerosis | |
JPH0139413B2 (en) | ||
JP2662607B2 (en) | Bicyclo [8.3.0] trideca-9,13-diene-2,7-diyne derivative | |
EP0641335A1 (en) | Free radical-catalyzed synthesis of benzoprostacyclins | |
KR890000376B1 (en) | Process for the preparation of alkanol esters of naproxen | |
JP2861157B2 (en) | Nicotinic acid derivative having substituent and method for producing the same | |
JPH0588693B2 (en) | ||
JPH0341456B2 (en) | ||
JPH05132478A (en) | New (1,3-dithiolane-2-ylidene) methylphenyl alkanoic acid derivative | |
JPH0372054B2 (en) |